379 related articles for article (PubMed ID: 20701541)
21. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
22. Dendritic cell immunotherapy combined with cytokine-induced killer cells promotes skewing toward Th2 cytokine profile in patients with metastatic non-small cell lung cancer.
Zhao P; Bu X; Wei X; Sun W; Xie X; Li C; Guo Q; Zhu D; Wei X; Gao D
Int Immunopharmacol; 2015 Apr; 25(2):450-6. PubMed ID: 25698555
[TBL] [Abstract][Full Text] [Related]
23. Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Yang Y; Lin H; Zhao L; Song Y; Gao Q
Immunotherapy; 2017 Jun; 9(8):629-635. PubMed ID: 28653574
[TBL] [Abstract][Full Text] [Related]
24. [Identification of immunological effector cells after autologous cytokine-induced killer cells treatment and its clinical implication in hepatocellular carcinoma patients].
Shi M; Zhang B; Tang ZR; Lei ZY; Wang HF; Feng YY; Liu JC; Fan ZP; Li HW; Mu JS; Wang FS
Zhonghua Yi Xue Za Zhi; 2003 Dec; 83(23):2049-53. PubMed ID: 14703414
[TBL] [Abstract][Full Text] [Related]
25. Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2008 Feb; 23(1):129-34. PubMed ID: 18298337
[TBL] [Abstract][Full Text] [Related]
26. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
[TBL] [Abstract][Full Text] [Related]
27. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
28. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
[TBL] [Abstract][Full Text] [Related]
29. [Growth inhibition of human hepatocellular carcinoma xenograft in nude mice by combined treatment with human cytokine-induced killer cells and chemotherapy].
Shi M; Yao L; Wang FS; Lei ZY; Zhang B; Li WL; Liu JC; Tang ZR; Zhou GD
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):465-8. PubMed ID: 15555334
[TBL] [Abstract][Full Text] [Related]
30. Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).
Gratama JW; Schmitz PI; Goey SH; Lamers CH; Stoter G; Bolhuis RL
Int J Cancer; 1996 Jan; 65(2):152-60. PubMed ID: 8567110
[TBL] [Abstract][Full Text] [Related]
31. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
32. Clinical study of autologous cytokine-induced killer cells for the treatment of elderly patients with diffuse large B-cell lymphoma.
Lu XC; Yang B; Yu RL; Chi XH; Tuo S; Tuo CW; Zhu HL; Wang Y; Jiang CG; Fu XB; Yang Y; Liu Y; Yao SQ; Dai HR; Cai L; Li BJ; Han WD
Cell Biochem Biophys; 2012 Jan; 62(1):257-65. PubMed ID: 21913005
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells.
Lin G; Wang J; Lao X; Wang J; Li L; Li S; Zhang J; Dong Y; Chang AE; Li Q; Li S
J Immunother; 2012 May; 35(4):337-43. PubMed ID: 22495391
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study of autologous cytokine induced killer cells combined with IL-2 for therapy of elderly patients with B-cell malignant lymphoma].
Yang B; Lu XC; Zhu HL; Han WD; Wang Y; Fan H; Li SX; Liu Y; Dai HR; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1244-9. PubMed ID: 21129269
[TBL] [Abstract][Full Text] [Related]
36. Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma.
Jäkel CE; Hauser S; Rogenhofer S; Müller SC; Brossart P; Schmidt-Wolf IG
Clin Dev Immunol; 2012; 2012():473245. PubMed ID: 23193418
[TBL] [Abstract][Full Text] [Related]
37. Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma.
Liu H; Li J; Wang F; Gao Y; Luo Y; Wang P; Li C; Zhu Z
Tumour Biol; 2015 Apr; 36(4):2299-307. PubMed ID: 25417201
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in metastatic brain tumor patients.
Li W; Wang Y; Zhao L; Xu L; Zhang Y; Mai L; Gao Q
Oncol Res Treat; 2015; 38(4):160-5. PubMed ID: 25877939
[TBL] [Abstract][Full Text] [Related]
39. [Short-term curative efficacy of autologous cytokine induced killer cells combined with low-dose IL-2 regimen containing immune enhancement by thymic peptide in elderly patients with B-cell chronic lymphocytic leukemia].
Cai LL; Yang Y; Yang B; Zhu HL; Lu XC; Zhang WY; Yu RL; Chi XH; Wang Y; Dai HR; Han WD; Fan H; Li SX; Liu Y; Ran HH; Lin J; Tuo S; Tuo CW; Zhang F; Cao JP; Yao SQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):564-70. PubMed ID: 22739156
[TBL] [Abstract][Full Text] [Related]
40. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
